BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21791476)

  • 21. PTPN2 improved renal injury and fibrosis by suppressing STAT-induced inflammation in early diabetic nephropathy.
    Li Y; Zhou H; Li Y; Han L; Song M; Chen F; Shang G; Wang D; Wang Z; Zhang W; Zhong M
    J Cell Mol Med; 2019 Jun; 23(6):4179-4195. PubMed ID: 30955247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2).
    Duval R; Bui LC; Berthelet J; Dairou J; Mathieu C; Guidez F; Dupret JM; Cools J; Chomienne C; Rodrigues-Lima F
    Sci Rep; 2015 Jun; 5():10750. PubMed ID: 26040922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
    Zahn M; Marienfeld R; Melzner I; Heinrich J; Renner B; Wegener S; Mießner A; Barth TF; Dorsch K; Brüderlein S; Möller P
    Blood; 2017 Mar; 129(11):1480-1490. PubMed ID: 28082443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
    Treanor LM; Zhou S; Janke L; Churchman ML; Ma Z; Lu T; Chen SC; Mullighan CG; Sorrentino BP
    J Exp Med; 2014 Apr; 211(4):701-13. PubMed ID: 24687960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiomics to investigate the mechanisms contributing to repression of PTPRC and SOCS2 in pediatric T-ALL: Focus on miR-363-3p and promoter methylation.
    Drobna-Śledzińska M; Maćkowska-Maślak N; Jaksik R; Kosmalska M; Szarzyńska B; Lejman M; Sędek Ł; Szczepański T; Taghon T; Van Vlierberghe P; Witt M; Dawidowska M
    Genes Chromosomes Cancer; 2022 Dec; 61(12):720-733. PubMed ID: 35778917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
    Lo FS; Kuo TT; Wang CJ; Kuo MT; Kuo MC
    Int J Hematol; 2008 Oct; 88(3):287-290. PubMed ID: 18758896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.
    Wendtner CM; Schmitt B; Gruss HJ; Druker BJ; Emmerich B; Goodwin RG; Hallek M
    Cancer Res; 1995 Sep; 55(18):4157-61. PubMed ID: 7545087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type.
    Asano N; Kinoshita T; Tamaru J; Ohshima K; Yoshino T; Niitsu N; Tsukamoto N; Hirabayashi K; Izutsu K; Taniwaki M; Morishima Y; Nakamura S
    Haematologica; 2011 Nov; 96(11):1636-43. PubMed ID: 21859738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The JAK3
    Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
    Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
    Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
    Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
    Wood GS; Hardman DL; Boni R; Dummer R; Kim YH; Smoller BR; Takeshita M; Kikuchi M; Burg G
    Blood; 1996 Sep; 88(5):1765-70. PubMed ID: 8781433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma.
    Pérez C; González-Rincón J; Onaindia A; Almaráz C; García-Díaz N; Pisonero H; Curiel-Olmo S; Gómez S; Cereceda L; Madureira R; Hospital M; Suárez-Massa D; Rodriguez-Peralto JL; Postigo C; Leon-Castillo A; González-Vela C; Martinez N; Ortiz-Romero P; Sánchez-Beato M; Piris MÁ; Vaqué JP
    Haematologica; 2015 Nov; 100(11):e450-3. PubMed ID: 26294736
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.
    Wellmann A; Otsuki T; Vogelbruch M; Clark HM; Jaffe ES; Raffeld M
    Blood; 1995 Sep; 86(6):2321-8. PubMed ID: 7662979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.
    Scharl M; Mwinyi J; Fischbeck A; Leucht K; Eloranta JJ; Arikkat J; Pesch T; Kellermeier S; Mair A; Kullak-Ublick GA; Truninger K; Noreen F; Regula J; Gaj P; Pittet V; Mueller C; Hofmann C; Fried M; McCole DF; Rogler G
    Inflamm Bowel Dis; 2012 May; 18(5):900-12. PubMed ID: 22021207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTPN2 Deficiency Enhances Programmed T Cell Expansion and Survival Capacity of Activated T Cells.
    Flosbach M; Oberle SG; Scherer S; Zecha J; von Hoesslin M; Wiede F; Chennupati V; Cullen JG; List M; Pauling JK; Baumbach J; Kuster B; Tiganis T; Zehn D
    Cell Rep; 2020 Jul; 32(4):107957. PubMed ID: 32726622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of
    Shaw AM; Qasem A; Naser SA
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis.
    Sarris AH; Luthra R; Papadimitracopoulou V; Waasdorp M; Dimopoulos MA; McBride JA; Cabanillas F; Duvic M; Deisseroth A; Morris SW; Pugh WC
    Blood; 1996 Sep; 88(5):1771-9. PubMed ID: 8781434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mining for JAK-STAT mutations in cancer.
    Constantinescu SN; Girardot M; Pecquet C
    Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.